pharmaceut ep downgrad unit state go sg websit
search growth
upsid tp
nc chang
despit attract product ibrance/canc diversif vaccin
consum exposur emerg market expect continu
trail peer term growth given still sizeabl tail portfolio
sale threat gener market appear concur
stock trade discount sector price-to-earnings hold reiter
keep busi grow hard work slightli outperform
pharma sector past month thank good news research
reshap maxim organ moreov new ceo rule big defens
deal see need move pipelin never good howev
consid perform group growth opportun expect top line
earn growth remain sector averag main growth driver ibranc
cancer eliqui anticoagul partner bm togeth account
total group sale term diversif vaccin inject consum combin
sale provid good visibl patent cliff/littl competit howev lyrica
neuropath pain face gener challeng enbrel inflamm compet
biosimilar sale togeth although upbeat qualiti pipelin
fail identifi product could make meaning contribut near futur
core scenario assum pipelin product gener less sale beyond
tail portfolio sale think benefit pfizer emerg
market footprint could struggl deliv meaning growth
big still tabl think plan deal also intend
becom focus perhap in-licens deal help
replenish pipelin even share profit said maxim never
say never come think option still tabl right
opportun aros said post celgene/bm transact less scope
pursu larg defens transact
hold reiter lower ep estim take conserv approach
sale eros gener perform rais oper cost
assumpt initi estim gener guidanc
stock trade discount pharma sector price-to-earnings reflect
slower earn growth vs estim beyond mid-to-high-singl
digit consensu conserv sale growth despit
profil potenti impact ebit best- worst-cas
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
diversif key product off-set gener
pressur short term
outperform us pharma sector past month
under-perform past three month due mix outlook
despit new ceo enthusiast comment pipelin improv big
challeng remain grow compani size given high contribut matur
portfolio sale come highli profit cash cow area tail product see
compani argu emerg market help would disagre unlik
suffici gener group growth sector averag fortun know
innov product ibranc see cancer novarti section
find right partner eliqui new oral anticoagul area bm see bayer
section detail view oral anticoagul landscap
rel diversifi sale gener outsid tradit prescript
medicin consum vaccin steril inject product via hospira
busi acquir consum put jv gsk compani intend
exit gradual vaccin almost single-product busi prevnar franchis
although success growth prospect remain weaker peer due patent
expiri product lyrica neuropath pain enbrel rheumatoid arthriti
combin sale presenc signific tail product account
total sale current declin low-single-digit pace
shown chart right main driver eliqui ibranc lesser extent
late-stag pipelin cancer pain due patent expiri compani
neg impact short term lyrica beyond eliqui
driver drag
pfizer ep growth remain slightli peer due soft top line
despit cost-contain measur success new product ibranc set becom
super-blockbust like eliqui although compani share profit latter improv
oper margin share buy-back programm assum
per year guid
estim close consensu short term conserv beyond
includ new product early-stag pipelin forecast
limit growth tail portfolio note slightli bullish group margin
assum cost-contain initi good track record area
revenuedeclin revenu consglob consglob averag
target price tp deriv averag sum-of-th part sotp valuat
dcf use wacc long-term adjust ebita margin perpetu
part
averag pharma premium innov
vaccin consum discount matur portfolio
sotp estim differ oper margin subdivis see bar chart
appli premium larg pharma sector ev/ebita multipl pharma
vaccin consum divis discount matur portfolio
sum part
number share
sotp show innov health sub-divis account almost half ev
given product longer patent life despit lower margin vs essenti
portfolio estim cash cow product
estim ebita margin sub-divis
sotp breakdown sub-divis per share base
share current trade peer forward price-to-earnings base
consensu averag discount tp compani would show
slight premium price-to-earnings
bull/bear approach show rather balanc profil group
show strong growth good visibl long term establish busi
good vaccin consum inject declin tail portfolio seem
control limit contribut pipelin upsid
downsid well
bull/bear scenario impact sale
bull/bear scenario impact ebita
bull/bear scenario impact sale categori
bull/bear scenario impact ebita categori
sever import pipelin news item notabl bavencio result
also interest given high unmet medic need conveni
studi evalu efficaci safeti subject
age year older moder sever atop dermat
random trial avelumab-cetuximab-radiotherapi versu soc
la scchn reach
head head line
studi lorlatinib versu crizotinib first line treatment
us monthli market share volum
impact
pressur biosimilar
stronger success twice penetr
slightli lower penetr
price pressur
approv
gradual penetr variou indic
approv
us mn
ih
vaccin
enbrel outsid canada
us mn
us mn except ep dp
product sold
net earn attribut sharehold
equival
total liabil equiti
chang work capit
flow oper activ
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
averag sotp averag ev/ebita us pharma multipl appli estim ebita subdivis premium
innov product premium vaccin consum discount matur portfolio dcf lt
downsid gener competit lyrica neuropath pain biosimilar enbrel inflamm presenc signific tail product
total sale
upsid stronger growth ibranc eliqui togeth group sale late-stag pipelin cancer pain
equiti rate dispers relationship
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
